More than 300 million people in the world suffer from clinical depression, but 50% of them will never seek treatment. Rather, these people suffer from such symptoms as sadness, inability to concentrate, and loss of appetite—with limited hope for improvement. Many individuals diagnosed with depression never admit that they need treatment in the first place. However, there are still others who recognize that they need depression treatment, but feel it is inaccessible to them.
When it comes to depression, no one is exempt—especially those at the tops of their industries. In fact, as a result of the stress that goes hand-in-hand with their careers, plus the personal characteristics that have enabled them to become successful in the first place, C-level executives, business leaders and entrepreneurs are perhaps more susceptible to depression than other people.
50 percent of patients diagnosed with depression do not respond to traditional antidepressants or psychotherapy, and a new study—the largest study of its kind—says it may have to do with genetics. Researchers from the University of North Carolina School of Medicine and University of Queensland studied the potential genetic risk factors of depression, and have linked 44 genes to the mental health disorder. Depression is the leading cause of disability for Americans between the ages of 15 and 44, and results in one million suicides annually.
In August 2016, Janssen Research & Development—a Janssen Pharmaceutical Company of Johnson & Johnson—announced that an isomer of ketamine, called esketamine, had received Breakthrough Therapy Designation by the Food & Drug Administration (FDA). Similarly to ketamine, esketamine has shown huge promise as a depression treatment, especially for those experiencing suicidal ideation, or who have resisted other treatment methodologies.